The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury

Keyphrases

• Tumor Necrosis Factor-α 100%
• Soluble Receptor 100%
• Arg-Gly-Asp 100%
• Liver Injury 100%
• Synthetic Analogues 100%
• Liver Cirrhosis 66%
• Integrin Receptor 66%
• Concanavalin A (Con A) 66%
• RGD Mimetics 66%
• Immune Response 33%
• Fibrosis 33%
• Infiltration 33%
• Glycoprotein 33%
• Liver 33%
• T Cells 33%
• Pathological Conditions 33%
• Cell Adhesion 33%
• Liver Tissue 33%
• Extracellular Matrix Protein 1 (ECM1) 33%
• Inflammatory Cells 33%
• Liver Damage 33%
• Immunostimulatory 33%
• Matrix-based 33%
• Immune Cells 33%
• TNF Receptor 1 (TNFR1) 33%
• Nonapeptides 33%
• Cholestatic Liver Disease 33%
• Effector Cells 33%
• RGD Motif 33%
• Cholestasis 33%
• Hepatitis 33%
• Cellular Interactions 33%
• Serum Transaminase 33%
• Thioacetamide 33%
• Necroinflammation 33%
• Target Epitope 33%
• Adhesion Motif 33%
• Autoimmune Hepatitis 33%
• SF 6 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Receptor 100%
• Tumor Necrosis Factor 100%
• Arginylglycylaspartic Acid 100%
• Experimental Liver Injury 100%
• Liver Cirrhosis 66%
• Integrin Receptor 66%
• Concanavalin A 66%
• Glycoprotein 33%
• Fibrosis 33%
• Adhesive Agent 33%
• Tumor Necrosis Factor Receptor 33%
• Epitope 33%
• Liver Injury 33%
• Liver Disease 33%
• Cholestasis 33%
• Aminotransferase 33%
• Thioacetamide 33%
• Autoimmune Hepatitis 33%